Abstract: Method and system for detecting stations in wireless local area networks having at least one access point configured to: upon transmission of an association response to a station, send a radio measurement request to the station performing active scanning of a SSID having a unique identifier univocally associated with a persistent MAC address of the station, upon reception of a probe request, check if the SSID field has a unique identifier univocally associated with a persistent MAC address of a station, and associate the source address of the probe request with the persistent MAC address of the station on a database of known stations; detect stations within the coverage area of the access point based on the information stored on the database of known stations.

Abstract: A device and method for the unambiguous identification of Wi-Fi devices is disclosed, by receiving probe request frames sent by Wi-Fi devices, extracting a set of features from a plurality of fields of each probe request frame, assigning a footprint to each probe request frame based on the extracted set of features, for each footprint, performing a cluster analysis on a time series of the sequence numbers included in the header of the probe request frames associated with the corresponding footprint, obtaining at least one cluster per footprint, identifying a Wi-Fi device for each different cluster, which identifies Wi-Fi devices that are not connected to a Wi-Fi network and employ MAC address randomization.

Abstract: A method, system and non-transitory computer-readable medium for the unambiguous identification of non-associated Wi-Fi devices, where upon receiving (102), by an access point (200), a probe request (202) from a Wi-Fi device (201) not associated to the access point (200), sending (104) a probe response (204) addressed to the non-associated Wi-Fi device (201), wherein the probe response (204) comprises a Hotspot 2.0 Indication element (206) including a ANQP Domain ID field (207) with a determined value; receiving (106), by the access point (200), an action frame (208) sent by the non-associated Wi-Fi device (201) in response to the Hotspot 2.0 Indication element (206) of the probe response (204); obtaining a static MAC address (209) of the non-associated Wi-Fi device (201) from the source address of the received action frame (208); and identifying (110) the non-associated Wi-Fi device (201) based on the obtained static MAC address (209).

Abstract: A method and system for handling roaming in train-to-trackside wireless networks including: receiving, by an access point (APi) currently associated with a train access terminal installed on-board a train, radio measurements of signals received by the train access terminal from access points of the train-to-trackside wireless network; determining a next access point (APnext) providing the highest signal quality (maxSQ); evaluating compliance with roaming criteria including: the next access point (APnext) is included in a list of candidate access points (Ni); the time elapsed since the last roaming exceeds a minimum permanency time (tp); the highest signal quality (maxSQ) exceeds the signal quality (SQ(i)) of the access point (APi) by a roaming margin; if the roaming criteria are met, sending a roaming command instructing the train access terminal to roam to the next access point (APnext).

Abstract: The present application provides novel compositions and methods for treating acute myeloid leukemia (AML). Compounds of the invention are acid ceramidase inhibitors, reduce AML cell viability, inhibit AML cell proliferation, increase cell death of AML cells, and induce apoptosis in AML cells. A primary compound of the invention is SACLAC: 2-chloro-N-((2S,3R)-1,3-dihydroxyoctadecan-2-yl)acetamide. The bromine analog of SACLAC (SABRAC: 2-bromo-N-((2S,3R)-1,3-dihydroxyoctadecan-2-yl)acetamide) is also useful for treating AML. SACLAC has much better activity than other know drugs used to treat AML.

Abstract: Method and system for detecting stations in wireless local area networks having at least one access point configured to: upon transmission of an association response to a station, send a radio measurement request to the station performing active scanning of a SSID having a unique identifier univocally associated with a persistent MAC address of the station, upon reception of a probe request, check if the SSID field has a unique identifier univocally associated with a persistent MAC address of a station, and associate the source address of the probe request with the persistent MAC address of the station on a database of known stations; detect stations within the coverage area of the access point based on the information stored on the database of known stations.

Abstract: A device and method for the unambiguous identification of Wi-Fi devices is disclosed, by receiving probe request frames sent by Wi-Fi devices, extracting a set of features from a plurality of fields of each probe request frame, assigning a footprint to each probe request frame based on the extracted set of features, for each footprint, performing a cluster analysis on a time series of the sequence numbers included in the header of the probe request frames associated with the corresponding footprint, obtaining at least one cluster per footprint, identifying a Wi-Fi device for each different cluster, which identifies Wi-Fi devices that are not connected to a Wi-Fi network and employ MAC address randomization.

Abstract: The present application provides novel compositions and methods for treating acute myeloid leukemia (AML). Compounds of the invention are acid ceramidase inhibitors, reduce AML cell viability, inhibit AML cell proliferation, increase cell death of AML cells, and induce apoptosis in AML cells. A primary compound of the invention is SACLAC: 2-chloro-N-((2S,3R)-1,3-dihydroxyoctadecan-2-yl)acetamide. The bromine analog of SACLAC (SABRAC: 2-bromo-N-((2S,3R)-1,3-dihydroxyoctadecan-2-yl)acetamide) is also useful for treating AML. SACLAC has much better activity than other know drugs used to treat AML.

Abstract: A novel gene (EPM2A) that is deleted or mutated in people with Lafora's disease is described. The EPM2A gene encodes a protein having an active catalytic site of a protein tyrosine phosphatase. Many different sequence mutations as well as several microdeletions in EPM2A have been found that co-segregate with Lafora's disease.

Abstract: A novel gene (EPM2A) that is deleted or mutated in people with Lafora's disease is described. The EPM2A gene encodes a protein having an active catalytic site of a protein tyrosine phosphatase. Many different sequence mutations as well as several microdeletions in EPM2A have been found that co-segregate with Lafora's disease.

Abstract: A novel gene (EPM2A) that is deleted or mutated in people with Lafora's disease is described. The EPM2A gene encodes a protein having an active catalytic site of a protein tyrosine phosphatase. Many different sequence mutations as well as several microdeletions in EPM2A have been found that co-segregate with Lafora's disease.

Abstract: A novel gene (EPM2A) that is deleted or mutated in people with Lafora's disease is described. The EPM2A gene encodes a protein having an active catalytic site of a protein tyrosine phosphatase. Many different sequence mutations as well as several microdeletions in EPM2A have been found that co-segregate with Lafora's disease.

Abstract: Aminocyclitol compounds and uses thereof as pharmaceutical compositions for the treatment of diseases associated with alterations in iNKT cells, more specifically autoimmune diseases, cancer, infections caused by pathogenic microorganisms or inflammatory diseases. Furthermore, the invention relates to the process for obtaining said compounds.

Abstract: The invention relates to a continuously variation gearbox formed by a casing (1) containing opposing input (2) and output (3) shafts, so that the gearbox can operate in both directions, such that the input shaft (2) is associated with a double constant velocity joint (4) provided with a sliding axle (5) which transmits movement to a head (6) positioned facing a disc (7) that rotates about the output shaft (3). The head (6) can move radially on the surface of the disc (7) with the aid of a carriage (8) and said head contains a plurality of equiangularly distributed pressure columns provided with driving bolts that emerge selectively under the action of a series of wheels mounted on a fork which tilts and comes into contact with one of said pressure columns, thereby causing the aforementioned driving bolt to emerge and generating the movement of the disc (7).

Abstract: A novel gene (EPMZA) that is deleted or mutated in people with Lafora's disease is described. The EPM2A gene encodes a protein having an active catalytic site of a protein tyrosine phosphatase. Many different sequence mutations as well as several microdeletions in EMP2A have been found that co-segregate with Lafora's disease.

Abstract: The present invention provides a systematic approach that allows health care providers (e.g., physicians) to use erythrocyte potassium measurements as an indicator of hypertension or risk of developing hypertension. In particular, the present invention provides systems and methods for treating conditions involving aberrant erythrocyte potassium levels (e.g., hypertension), preventing the onset of conditions involving aberrant erythrocyte potassium levels, identifying individuals at risk for developing hypertension, and evaluating the effectiveness of treatments for conditions involving aberrant erythrocyte potassium levels (e.g., hypertension).

Abstract: A novel gene (EPM2A) that is deleted or mutated in people with Lafora's disease is described. The EPM2A gene encodes a protein having an active catalytic site of a protein tyrosine phosphatase. Many different sequence mutations as well as several microdeletions in EPM2A have been found that co-segregate with Lafora's disease.

Abstract: A pharmaceutical composition comprising an effective amount of at least one (a) an effective amount of at least one 3,5-diamino-6-chloro-N-(diaminomethylene) pyrazinecarboxamide monohydrochloride, dihydrate derivative comprising pirazinoylguanidine, benzamil, dichlorobenzamil, 5-(N,N-dimethyl)-Amiloride, 5-(N-ethyl-N-isopropyl)-Amiloride, (N,N-hexamethylene)-Amiloride, 5-(N-methyl-N-isobutyl)-Amiloride, and Amiloride citrate; (b) an effective amount of a calcium increasing agent; and (c) a pharmaceutically acceptable excipient. Methods are provided for treating a cardiovascular disease (CVD) in a patient diagnosed as having CVD or at risk for developing CVD, the method comprising administering to a subject in need of such treatment a therapeutically effective amount of at least one of 3,5-diamino-6-chloro-N-(diaminomethylene) pyrazinecarboxamide monohydrochloride, dihydrate and/or a derivative thereof.

Abstract: A novel gene (EPM2A) that is deleted or mutated in people with Lafora's disease is described. The EPM2A gene encodes a protein having an active catalytic site of a protein tyrosine phosphatase. Many different sequence mutations as well as several microdeletions in EPM2A have been found that co-segregate with Lafora's disease.

Abstract: Lafora's disease in humans is characterized by the mutation or deletion of an EPM2A gene, which encodes a protein, Laforin, having a tyrosine phosphatase domain. Many different sequence mutations, including microdeletions, in EPM2A co-segregate with, Lafora's disease. Accordingly, detection of mutations in EPM2 are useful in diagnosing Lafora's disease.